Myung Gull Lee

Myung Gull Lee

Auto-generated profile, based on publicly available information

Myung Gull Lee

Seoul National University

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
YCYoung H. Choi
Young H. Choi
SKSang G. Kim
Sang G. Kim
MLMyung G. Lee
Myung G. Lee

1 January 2010 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
JLJoo H. Lee
Joo H. Lee
SYSi H. Yang
Si H. Yang
JOJung Mi Oh
Jung Mi Oh
MLMyung G. Lee
Myung G. Lee
Objectives In rats with diabetes mellitus induced by alloxan (DMIA) or streptozocin (DMIS), changes in the cytochrome P450 (CYP) isozymes in the liver, lung, kidney, intestine, brain, and testis have been reported based on Western blot analysis, Northern blot analysis, and various enzyme activities. Changes in phase II enzyme activities have been reported also. Hence, in this review, changes in the pharmacokinetics of drugs that were mainly conjugated and metabolized via CYPs or phase II isozymes in rats with DMIA or DMIS, as reported in various literature, have been explained. The changes in the pharmacokinetics of drugs that were mainly conjugated and mainly metabolized in the kidney, and that were excreted mainly via the kidney or bile in DMIA or DMIS rats were reviewed also. For drugs mainly metabolized via hepatic CYP isozymes, the changes in the total area under the plasma concentration–time curve from time zero to time infinity (AUC) of metabolites, AUCmetabolite/AUCparent drug ratios, or the time‐averaged nonrenal and total body clearances (CLNR and CL, respectively) of parent drugs as reported in the literature have been compared. Key findings After intravenous administration of drugs that were mainly metabolized via hepatic CYP isozymes, their hepatic clearances were found to be dependent on the in‐vitro hepatic intrinsic clearance (CLint) for the disappearance of the parent drug (or in the formation of the metabolite), the free fractions of the drugs in the plasma, or the hepatic blood flow rate depending on their hepatic extraction ratios. The changes in the pharmacokinetics of drugs that were mainly conjugated and mainly metabolized via the kidney in DMIA or DMIS rats were dependent on the drugs. However, the biliary or renal CL values of drugs that were mainly excreted via the kidney or bile in DMIA or DMIS rats were faster. Summary Pharmacokinetic studies of drugs in patients with type I diabetes mellitus were scarce. Moreover, similar and different results for drug pharmacokinetics were obtained between diabetic rats and patients with type I diabetes mellitus. Thus, present experimental rat data should be extrapolated carefully in humans.

30 September 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
YKYu Chul Kim
Yu Chul Kim
ALAe Kyung Lee
Ae Kyung Lee
JLJoo Hyun Lee
Joo Hyun Lee
ILInchul Lee
Inchul Lee
DLDuk-Chul Lee
Duk-Chul Lee
MLMyung Gull Lee
Myung Gull Lee

1 October 2000 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
HSHyun J. Shim
Hyun J. Shim
ELEun J. Lee
Eun J. Lee
SKSoon H. Kim
Soon H. Kim
MYMoohi Yoo
Moohi Yoo
JKJong W. Kwon
Jong W. Kwon
MLMyung G. Lee
Myung G. Lee


1 May 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJee H. Shin
Jee H. Shin
KCKa Y. Choi
Ka Y. Choi
YKYu C. Kim
Yu C. Kim
MLMyung G. Lee
Myung G. Lee
The dose-dependent pharmacokinetics of itraconazole after intravenous (10, 20, or 30 mg/kg) and oral (10, 30, or 50 mg/kg) administration and the first-pass effects of itraconazole after intravenous, intraportal, intragastric, and intraduodenal administration at a dose of 10 mg/kg were evaluated in rats. After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 μg · min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg). After oral administration, the AUC0-∞was significantly different for three oral doses (380, 687, and 934 μg · min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg). The extent of absolute oral bioavailability (F) was 34.9% after an oral dose at 10 mg/kg. The AUC0-∞(or AUC0-8 h) values were comparable between intravenous and intraportal administration and between intragastric and intraduodenal administration, suggesting that the hepatic and gastric first-pass effects were almost negligible in rats. However, the AUC0-8 hvalues after intraduodenal and intragastric administration were significantly smaller than that after intraportal administration, approximately 30%, suggesting that the intestinal first-pass effect was approximately 70% of that of an oral dose of 10 mg/kg. The lowFafter oral administration of itraconazole at a dose of 10 mg/kg could be mainly due to the considerable intestinal first-pass effect.